| Filed On | Filing |
|---|---|
| 16 Oct 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by PharmaCyte Biotech, Inc. under Item 4.01 of its Form 8-K dated October 16, 2026. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with ot... |
| 14 Sep 2026 | FORM 10-Q FOR JUL 2026 |
| 29 Jul 2026 | FORM 10-K FOR APRIL 2026 |
| 17 Jul 2026 |
Form 4/A: Walker Wayne Remell, Director
Acquired 0 Stock Option (Right to Buy) (Other Transaction) |
| 17 Jul 2026 |
Form 4/A: Abecassis Michael M, Director
Acquired 0 Stock Option (Right to Buy) (Other Transaction) |
| 17 Jul 2026 |
Form 4/A: Schechter Jonathan, Director
Acquired 0 Stock Option (Right to Buy) (Other Transaction) |
| 17 Jul 2026 |
Form 4/A: Weinstein Robert, Director
Acquired 0 Stock Option (Right to Buy) (Other Transaction) |
| 02 Apr 2026 |
Form 4: Weinstein Robert, Director
Granted 119,170 Stock Option (Right to Buy) |
| 02 Apr 2026 |
Form 4: Walker Wayne Remell, Director
Granted 119,170 Stock Option (Right to Buy) |
| 02 Apr 2026 |
Form 4: Schechter Jonathan, Director
Granted 119,170 Stock Option (Right to Buy) |
| 02 Apr 2026 |
Form 4: Abecassis Michael M, Director
Granted 119,170 Stock Option (Right to Buy) |
| 02 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 18 Mar 2026 | SCHEDULE 13G |
| 18 Mar 2026 | Form 4: PharmaCyte Biotech, Inc., 10% owner · Femasys Inc |
| 17 Mar 2026 | FORM 10-Q FOR JAN 2026 |
| 09 Mar 2026 | ANNUAL REPORT |
| 09 Mar 2026 |
Proxy statement: annual meeting on March 30, 2026
CEO pay $520K, down 37% · say-on-pay vote |
| 27 Feb 2026 | PRELIMINARY PROXY STATEMENT |
| 13 Feb 2026 | SCHEDULE 13G/A |
| 07 Jan 2026 |
Form 4: Silverman Joshua, Director
Bought 30,000 shares ($23.5K) · Bought 30,000 shares ($23.7K) · Bought 40,000 shares ($33.3K) |
Loading...
